ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel.
Abstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 71 citations in OpenAlex.
- Small-Molecule Kinase Inhibitors Modulating Circadian Rhythms.Medicinal research reviews · 2026Review
- Structure-Activity Relationship Studies Resulting in the Identification of Potent and Selective Salt-Inducible Kinase Inhibitors.ACS medicinal chemistry letters · 2026Article
- Transcriptomic analysis of tissue-resident memory T cells of the fallopian tube reveals a precursor immune surveillance network for ovarian cancer prevention.Nature communications · 2026Article
- Inhibition of SIK2 and SIK3 induces adaptive ER-phagy and creates a therapeutic vulnerability in ovarian cancer.Research square · 2026Article
- Targeting programmed cell death: a novel therapeutic paradigm for cancer based on mode-of-death classification.Apoptosis : an international journal on programmed cell death · 2026Review
- Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer.Nature immunology · 2026Article
- Salt-inducible kinases as druggable targets for immunotherapy of ovarian cancer.Nature immunology · 2026Article
- A Review of SIK2 in Ovarian Cancer: Function and Emerging Targeted Therapies.OncoTargets and therapy · 2026Review
- The Role of the Salt-inducible Kinases in the Endocrine Glands.Endocrinology · 2025Review
- Advanced modeling of salt-inducible kinase (SIK) inhibitors incorporating protein flexibility through molecular dynamics and cross-docking.Scientific reports · 2025Article
- Salt-inducible kinase 2 confers radioresistance in colorectal cancer by facilitating homologous recombination repair.MedComm · 2025Article
- SIK2 activates the autophagy‒apoptosis pathway through SP1 regulation to inhibit the progression of hepatocellular carcinoma.Frontiers in pharmacology · 2025Article
- SIK2 inhibitor SIC-19 enhances the sensitivity of PARP inhibitors in triple-negative breast cancers and pancreatic cancers.Oncology research · 2025Article
- Role of SIK1 in tumors: Emerging players and therapeutic potentials (Review).Oncology reports · 2024Review
- Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases.Journal of medicinal chemistry · 2024Article
- A Recipe for Successful Metastasis: Transition and Migratory Modes of Ovarian Cancer Cells.Cancers · 2024Review
- Optimization of Selectivity and Pharmacokinetic Properties of Salt-Inducible Kinase Inhibitors that Led to the Discovery of Pan-SIK Inhibitor GLPG3312.Journal of medicinal chemistry · 2024Article
- Identification of highly selective SIK1/2 inhibitors that modulate innate immune activation and suppress intestinal inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Understanding the roles of salt-inducible kinases in cardiometabolic disease.Frontiers in physiology · 2024Review
- Roles of salt‑inducible kinases in cancer (Review).International journal of oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 4 countries.
Jinhua ZhouDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Albandri AlfraidiDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Shu ZhangDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Janice M Santiago-O'FarrillDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Venkata Krishna Yerramreddy ReddyArrien Pharmaceuticals, Salt Lake City, Utah.
Abdulkhaliq AlsaadiThe Nuffield Department of Obstetrics and Gynecology, University of Oxford, Oxford, United Kingdom.
Ahmed A AhmedThe Nuffield Department of Obstetrics and Gynecology, University of Oxford, Oxford, United Kingdom.
Hailing YangDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jinsong LiuDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Weiqun MaoDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yan WangDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hiroshi TakemoriNational Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Osaka, Japan.
Hariprasad VankayalapatiArrien Pharmaceuticals, Salt Lake City, Utah.
Zhen LuDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Robert C BastDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. rbast@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USArrien Pharmaceuticals (United States) · USNuffield Orthopaedic Centre · GBNational Institute of Biomedical Innovation, Health and Nutrition · JP
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0MTexas Center for Cancer NanomedicineU54CA151668 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2010 to 2014
$12.4MU.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2021
$7.9MSupplement to CA135354 "ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer"R01CA135354 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 2009 to 2019
$3.5MNovel extra cellular RNA-based combinatorial RNA inhibition therapyUH3TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2015 to 2017
$3.2MNovel extra cellular RNA-based combinatorial RNA inhibition therapyUH2TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2013 to 2014
$1.1MMedical Research Council G0902418NCATS NIH HHS UH2 TR000943NCATS NIH HHS UH3 TR000943NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA217685NCI NIH HHS R01 CA135354NCI NIH HHS U54 CA151668
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic AgentsApoptosisCell Line, TumorCentrosomeDrug SynergismFemaleGene Knockdown TechniquesHumansImmunohistochemistryMiceMice, NudeOvarian NeoplasmsPaclitaxelProtein Serine-Threonine KinasesTissue Array AnalysisAntineoplastic AgentsPaclitaxelProtein Serine-Threonine Kinasessalt-inducible kinase-2, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.